Brandsymbol’s Post

Today, Teva and Sanofi announced positive topline results from our Phase 2b anti-TL1A study investigating a potentially best-in-class treatment option for moderate-to-severe inflammatory bowel diseases (IBD), in patients with ulcerative colitis (UC) and Crohn’s disease (CD). Our commitment to better health for patients is what drives our innovative medicines portfolio, and with approximately 4.9 million cases globally, those living with #IBD are in need of new treatment options. Read more about our anti-TL1A program, and what’s coming next: https://ow.ly/JBWC50UsvYw #TevaPharm #PivotToGrowth #Innovation #UlcerativeColitis #CrohnsDisease

What an incredible way to cap off 2024! I am extremely proud of today’s announcement, with our anti-TL1A therapy meeting primary endpoints in both UC and CD. After we were able to accelerate timing of our Phase 2b trial, this is an encouraging step on the path to potentially bringing a best-in-class treatment to support patients living with #IBD. This is a thrilling milestone for us at Teva R&D, and demonstrates how strategic partnerships can further fuel our innovative medicines portfolio and help us deliver on our #PivotToGrowth strategy. The future of R&D is now, and I can’t wait to see where we go in 2025! #TogetherWeCanHelpPatients #InnovativeMedicines #TevaRnDThePlaceToBe #TevaPharm #WeAreAllInForBetterHealth

AstraZeneca Presents the Analysis of P-IIIb (BATURA) Trial Assessing Airsupra (Albuterol/Budesonide) for Intermittent or Mild Persistent Asthma #astrazeneca #airsupra #albuterol #budesonide #asthma #clinicaltrial #piii #batura #rescuemedication

Good news for people living with #IBD! Important news today from Teva Pharmaceuticals and Sanofi regarding our Phase 2b study investigating duvakitug, a monoclonal antibody targeting TL1A for the treatment of moderate-to-severe inflammatory bowel disease (IBD). The study met the primary endpoints in ulcerative colitis (UC) and Crohn’s disease (CD) and results show best-in-class potential! Important step forward for the approximately 4.9 million patients living with #IBD, a giant leap for Teva’s #InnovativeMedicines portfolio and the advancement of our #PivotToGrowth strategy. Read more about our anti-TL1A program, and what’s coming next. #TevaPharm #PivotToGrowth #Innovation #UlcerativeColitis #CrohnsDisease

Respiratory and nasal challenge tests in a clinical trial can expedite drug development by demonstrating target engagement and efficacy prior to patient exposure in a relatively small study in a well-controlled environment. In addition, bioavailability assessment during a nasal allergen assessment is essential for drugs intranasally administered. Learn about the merits and limitations of various respiratory and nasal challenge tests: https://lnkd.in/eXNC4pAC https://lnkd.in/gGJbzGP #RespiratoryChallenge #AllergenChallenge #RespiratoryCenterOfExcellence #BelfastClinic

As we get set to close out the year, I’m pleased to share Teva Pharmaceuticals’s positive topline results for our anti-TL1A therapy (duvakitug) for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), the two most common types of inflammatory bowel disease (#IBD). IBD places a tremendous burden and impacts the daily lives of approximately 4.9 million patients globally. At the heart of our #PivotToGrowth journey is a passion to be #AllInforBetterHealth, and everyone at Teva Pharmaceuticals is motivated to deliver solutions that can make a real difference in the lives of our patients. Our collaboration and strategic partnership with Sanofi stand as a proof point that, as Teva grows its innovative business, we are becoming a partner of choice and cementing our reputation as a true industry leader. I want to thank our global teams for their relentless focus on innovation and execution. Your dedication is central to our progress and reinforces Teva’s promising future. We will continue to invest in science and innovative medicines that improve patient outcomes worldwide. Read more about it here: https://lnkd.in/eR4jmvzR #InnovationForPatients #TevaPharm #Investors #Innovation

Breaking: The biggest drug driving Sanofi’s and Regeneron’s businesses is about to get a bit bigger. On Friday, the FDA approved Dupixent as an add-on to typical inhaled medicines for patients with inadequately controlled COPD, or chronic obstructive pulmonary disease, and high levels of a type of white blood cell called eosinophils. The antibody was already expected to surpass $14 billion in 2024 sales, and analysts see the COPD market being a multibillion-dollar opportunity for Dupixent. On the "next chapter" for Dupixent:

Respiratory and nasal challenge tests in a clinical trial can expedite drug development by demonstrating target engagement and efficacy prior to patient exposure in a relatively small study in a well-controlled environment. In addition, bioavailability assessment during a nasal allergen assessment is essential for drugs intranasally administered. Learn about the merits and limitations of various respiratory and nasal challenge tests: https://lnkd.in/eXNC4pAC https://lnkd.in/gGJbzGP #RespiratoryChallenge #AllergenChallenge #RespiratoryCenterOfExcellence #BelfastClinic

Respiratory and nasal challenge tests in a clinical trial can expedite drug development by demonstrating target engagement and efficacy prior to patient exposure in a relatively small study in a well-controlled environment. In addition, bioavailability assessment during a nasal allergen assessment is essential for drugs intranasally administered. Learn about the merits and limitations of various respiratory and nasal challenge tests: https://lnkd.in/eXNC4pAC https://lnkd.in/gGJbzGP #RespiratoryChallenge #AllergenChallenge #RespiratoryCenterOfExcellence #BelfastClinic

Big News Alert GSK's new asthma drug, Depemokimab, is showing promise in its latest trial! Depemokimab is a long-term solution for asthma treatment, shown to reduce attacks for those with severe eosinophilic asthma, requiring only two injections per year. This breakthrough could mean fewer hospital visits and a better quality of life for many. At NiHowdy, we're committed to keeping you informed about the latest advancements in healthcare. Don't forget to check out our prescription discount card and Bitcoin rebates to save on your medications. What are your thoughts on this new treatment? Share your opinions and experiences in the comments below. Join the #ZeroCostPrescription movement with NiHowdy today! Visit NiHowdy.com for more details. #HealthCare #AsthmaTreatment #NiHowdy #GSK #Depemokimab #Innovation #BitcoinRebates #CommunityHealth